

(Translation)

Minutes of 2026 Annual General Meeting of Shareholders

Inter Pharma Public Company Limited

Meeting Time & Venue

Inter Pharma Public Company Limited ("the Company") held the 2025 Annual General Meeting of Shareholders on Monday, April 27, 2026 at 14.00 hrs., via electronic broadcast live (E-Meeting) from the meeting room of Inter Pharma Public Company Limited, 140/9 ITF Tower, 9 Floor, Silom Road, Suriyawong, Bangrak, Bangkok 10500

Meeting started at 14.00 hrs.

Clinical Professor Emeritus Dr. Udom Kachintorn, Chairman of the Board of Directors, presided as the Chairman of the meeting thanked the shareholders for attending the 2026 Annual General Meeting of Shareholders of the Company via electronic means (E-Meeting) only. The Chairman opened the meeting and assigned Ms. Chompunuch Meevang, the Company Secretary, as the moderator of the meeting.

The Company Secretary informed the meeting that the 2026 Annual General Meeting of Shareholders will be conducted via electronic means (E-Meeting) only. The Company has complied with the Royal Decree on Electronic Conferencing B.E. 2020 and the Notification of the Ministry of Digital Economy and Society on Security Standards of Electronic Conferencing B.E. 2020. In this meeting the company has assigned Quidlab Co., Ltd., a service provider that has received a certificate for the electronic conferencing control system. According to the information security standard of the Electronic Transactions Development Agency's Conference Control System Register Counting votes in the Annual General Meeting of Shareholders, including organizing the meeting via electronic media system (E-Meeting) and the meeting was recorded in video.

Quorum

The Company Secretary informed the meeting that the meeting, 8 shareholders were presence in person, representing 211,176,031 shares, and 22 shareholders by proxy, representing 127,241,231 shares. In total, 30 shareholders, holding a total of 338,417,262 shares, equivalent to 55.9049 percent of the common shares, which constituted a quorum pursuant to the Company's Articles of Association no. 39 and representing at least one-thirds of shares distributed shall be required.

The Company Secretary introduced to the meeting, the directors, managements, auditors from EY Office Limited and representatives of the auditor being witnesses. These persons were as follows:

Directors attending the meeting at the meeting venue:

- | | | | |
|----|---|-----------------|---|
| 1. | Clinical Professor Emeritus Dr. Udom Kachintorn | | Chairman of the Board of Directors/
Independent Director/ Chairman of the
Corporate Governance and Sustainable
Development Committee |
| 2. | Dr. Trinnawat | Thanitnithiphan | Director/ Nomination and Remuneration
Committee/ Risk Management Committee/
Chairman of the Executive Committee and
Chief of Executive Officer |
| 3. | Prof. Dr. Sansanee | Chaiyaroj | Independent Director/ Audit Committee/
Chairman of the Risk Management
Committee/ Corporate Governance and
Sustainable Development Committee |
| 4. | Dr. Pao | Sriprasertsuk | Independent Director/ Audit Committee/
Nomination and Remuneration Committee/
Corporate Governance and Sustainable
Development Committee |
| 5. | Mrs. Apimon | Posri | Director/ Executive Committee and Human
Resource Director |
| 6. | Ms. Napaporn | Dechakarat | Director/ Risk Management Committee/
Executive Committee and COO |

Directors attending the meeting via electronic means

- | | | | |
|----|--------------|-------------|---|
| 1. | Mr. Kamtorn | Sila-on | Independent Director/ Chairman of the Audit
Committee/ Chairman of Nomination and
Remuneration Committee / Corporate
Governance and Sustainable Development
Committee |
| 2. | Dr. Nat | Ativitavas | Director |
| 3. | Dr. Yutthana | Suwannachot | Director |

Directors attending the meeting: All 9 persons (equivalent to 100 percent of the total Board members)

Management and Others Related:

- | | | | |
|----|----------------|-----------|---------------------------------|
| 1. | Ms. Chatkaew | Krudkosol | Acting to Chief Finance Officer |
| 2. | Ms. Chompunuch | Meevang | Company Secretary |

Auditors from EY Office Limited:

Ms. Siriwan Nitdamrong

Representatives of the Auditor being Witnesses during the Voting Process:

Ms. Jintana

Umpornpa-nga

In the meantime, the Company Secretary informed the meeting that the 2026 Annual General Meeting of Shareholders has 12 agenda items as detailed in the invitation letter sent to all shareholders by the Company and has been published on the Company's website. The Company provides an opportunity for shareholders to propose agendas and nominate candidates to be elected as directors during October 1, 2025 - December 31, 2025, in which there were no shareholders proposing agendas and nominate names of persons to be considered for election as a director.

The Company Secretary has clarified the details of the voting method and raising questions can be summarized as follows:

1. In voting of today's meeting, each shareholder has the right to vote which equivalent to the number of shares held. By counting 1 share equal to 1 vote and the shareholders have the right to vote on each agenda to agree, disagree or abstain in just one way or another.
2. In counting the votes, the Company counts the votes of the shareholders who register to attend the meeting via electronic media by pressing one of the voting buttons; agree, disagree or abstain in each agenda at any time when the agenda is not closed. After the agenda is closed, if the shareholders do not press the voting button, the system will consider that the shareholders is agreed and cannot change the voting.
3. In addition, for the proxies whose voters have already specified their voting for each agenda item in the proxy form, the Company has counted your votes from the proxy form. This is for the convenience of shareholders.
4. For reading the voting results in each agenda, the Chairman and or the Company Secretary will inform the meeting of the voting results of each agenda. The results of the votes will be the votes that include the votes of the shareholders who attend the meeting, both in person and by proxy. Each agenda will use the number of shares of the latest attendees in that agenda.
5. In each agenda, there will be an opportunity for shareholders to ask questions by sending questions through typing in texts or sending voice messages. In doing so, the shareholders have to click on the Question Menu, type your message in the text box. If shareholders have experienced any problems during the electronic meeting, please contact Quidlab Company Limited at 02-013-4322 or email: info@quidlab.com.

In this regard, The Company reserves the right to consider and select questions as appropriate in case of a large number of questions being sent into the system, if there are any questions that cannot be answered during the meeting due to limited time. The Company will consider collecting, answering and disclosing in the minutes of the shareholders' meeting. which the company will disseminate through the information system of the Stock Exchange of Thailand and on the Company's website within 14 days from the date of the shareholders' meeting.

When shareholders are aware and have no other opinion on the voting method and asking questions as presented above, the Chairman shall proceed the meeting according to the agenda as follows:

Agenda 1 To certify the Minutes of the 2025 Annual General Meeting of Shareholders

The Chairman assigned Ms. Chompunuch Meevang, the Company Secretary, to inform the Meeting of the details regarding this agenda.

The Company Secretary informed the meeting that the Company had convened the 2025 Annual General Meeting of Shareholders on April 28, 2025 and had prepared the minutes of such meeting. The Board of Directors had considered and resolved that the minutes were accurately and completely recorded in accordance with the resolutions of the meeting. The Company had already delivered the minutes to all shareholders together with the notice of this meeting. (Details appear in Attachment No. 1.)

The Chairman gave the shareholders an opportunity to ask questions and express their opinions. There were no shareholders inquiring or expressing opinions on this agenda item.

The Chairman proposed the meeting to consider approving the Minutes of the 2025 Annual General Meeting of Shareholders.

Meeting Resolution: The meeting considered and unanimously resolved to certify the Minutes of the 2025 Annual General Meeting of Shareholders with the following votes:

Agree	338,433,512	votes	% equivalent to	100.0000
Disagree	0	votes	% equivalent to	0.0000
Abstain	0	votes	% equivalent to	0.0000

Remark: In this agenda item, one additional shareholder attended the meeting, representing 16,250 shares. Accordingly, the total number of shareholders attending the meeting was 31, representing 338,433,512 shares with voting rights, equivalent to 55.9076 percent.

Agenda 2 To acknowledge the reports of board of directors and operating results for the year ended 31 December 2025

The Chairman assigned Ms. Chatkaew Krudkosol, Acting to Chief Finance Officer, to inform the Meeting of the details regarding this agenda

Ms. Chatkaew Krudkosol informed the Meeting that the Company's performance for the year 2025 is as follows:

The Company reported total revenue from sales and services of 2,193.5 million baht, an increase of 296.2 million baht or 15.6 percent from the previous year. The revenue was categorized by business segment as follows:

1. Hospital Market Healthcare generated revenue of 318 million baht, increasing by 83 million baht or 35 percent from the previous year.

2. Consumer Market Healthcare generated revenue of 465 million baht, increasing by 43 million baht or 10 percent from the previous year.

3. Animal Healthcare generated revenue of 374 million baht, increasing by 23 million baht or 7 percent from the previous year.

4. Pharmacy Business generated revenue of 684 million baht, increasing by 40 million baht or 6 percent from the previous year.

5. Hospital Business generated revenue of 215 million baht, increasing by 26 million baht or 14 percent from the previous year.

6. Medical equipment of rehabilitation medicine generated revenue of 138 million baht, increasing by 57 million baht or 142 percent from the previous year.

The Company reported gross profit of 900.2 million baht, an increase of 190 million baht or 27 percent from the previous year, with the gross profit margin increasing by 4 percent compared to the previous year. Selling and administrative expenses amounted to 728.8 million baht, increasing by 78.7 million baht or 12 percent from the previous year. The Company recorded net profit of 136.1 million baht, an increase of 99 million baht or 271 percent from the previous year.

The Company would like to report on the progress of operations in 2025, which are detailed as follows:

- Drug Care Co., Ltd. had a total of 48 branches as of December 31, 2025, and plans to expand by an additional 4 branches in 2026.
- Nakornpat Inter Hospital appointed a consultant on January 16, 2026, to prepare for Hospital Accreditation (HA) Step 1–2 certification.
- The Company participated in the Listed Company Value Enhancement Program (JUMP+) in 2025 and disclosed its business plan through the SET system on March 27, 2026.

The Company Secretary inform that the Company is highly emphasize on anti- corruption. The Company has created an anti-corruption policy to serve as a guideline for the conduct of directors, executives, and employees of the Company. which must be strictly adhered to. If there are any clues about corruption or complaints related to the Company's business can be notified via email: comsec@interpharma.co.th or deliver by post to the Company's address. In the past, the Company has not found any complaints related to corruption or related to the Company's business.

The Chairman then invited the shareholders to express their opinions and raise questions relating to this agenda item. As there were no further questions from the shareholders.

This agenda item was acknowledged by the meeting.

Agenda 3 To consider and approve the financial statements for the year ended 31 December 2025

The Chairman assigned Ms. Chatkaew Krudkosol, Acting to Chief Finance Officer, to inform the Meeting of the details regarding this agenda

Ms. Chatkaew Krudkosol informed the Meeting that the Company has prepares the Financial Statements for the year ended 31 December 2025, as duly audited and certified by the auditor from EY Office Limited and reviewed by the Audit Committee. The summary of the Company's financial status and performance during the year 2025 is as follows:

		Consolidated Financial Statement		Separate Financial Statement	
		2025	2024	2025	2024
Total Assets	(Million Baht)	3,238.81	3,026.84	2,311.86	2,225.68
Total Liabilities	(Million Baht)	939.83	869.06	310.74	298.09
Total Revenue	(Million Baht)	2,214.06	1,911.95	734.75	653.47
Profit (Loss) for the year	(Million Baht)	136.07	36.63	73.65	25.31
Earning (Loss) per share	(Baht : Share)	0.202	0.061	0.122	0.042

The Chairman then invited the shareholders to express their opinions and raise questions relating to this agenda item. However, no shareholders expressed any opinions or raised any questions regarding this agenda item.

The Chairman therefore requested the meeting to consider and approve the Company's financial statements for the year ended 31 December 2025.

Meeting Resolution: The meeting considered and resolved to approved the annual financial statements for the year ended 31 December 2025 as proposed with the following votes:

Agree	356,874,112	votes	% equivalent to 100.0000
Disagree	0	votes	% equivalent to 0.0000
Abstain	0	votes	% equivalent to 0.0000

Remark: In this agenda item, one additional shareholder attended the meeting, representing 18,440,600 shares. Accordingly, the total number of shareholders attending the meeting was 32, representing 356,874,112 shares with voting rights, equivalent to 58.9539 percent.

Agenda 4 To consider and approve the allocation of profit as legal reserve and dividend payment for the year 2025

The Chairman assigned Ms. Chompunuch Meevang, Company Secretary, to inform the Meeting of the details regarding this agenda.

The Company Secretary informed the Meeting that according to Section 115 of the Public Limited Company Act B.E. 2535 (1992) (as amended) and Article 51 of the Company's Articles of Association,

provide that no dividends shall be paid other than out of profits. The Company's policy is to pay dividends at the rate of not less than 50 percent of the net profits after deducting the legal reserves and, provided that dividend payment will be subjected to the Company's cash flow, investment plan, conditions and terms of agreements to which the Company is bound, as well as the necessity and other appropriateness in the future.

And according to Section 116 of the Public Limited Company Act B.E. 2535 (1992) (including any amendment thereto) and Article 53 of the Company's Articles of Association, the Company must allocate part of the annual net profit as reserve fund in an amount not less than 5 percent of the annual net profit less the sum of accumulated loss brought forward (if any) until the reserve fund amounts to be not less than 10 percent of the registered capital.

The Board of Directors deemed it appropriate to propose to the Annual General Meeting of Shareholders to approve the allocation of net profit for the year 2025 at the rate of Baht 0.073 per share for a total of 605,344,475 shares, amounting to approximately 44.19 million baht in total, or equivalent to 60 percent of the net profit after the deduction of all types of reserves as required by the Company's Articles of Association and applicable laws. This is in accordance with the Company's dividend payment policy. The Board also approved the allocation of Baht 3.68 million from the net profit for 2025 as a statutory reserve.

The Board of Directors has set the Record Date on May 7, 2026 to determine the name of shareholders who are entitled to receive the dividend and to pay the dividend on May 25, 2026.

The comparison of dividend payments during the past 3 years is detailed as follows:

Description	2025 (proposed year)	2024	2023
Dividend Payment (Million Baht)	44.19	-	129.376
● Dividend for year (Baht : share)	0.073	-	0.3473
○ Stock Dividend Payout Ratio (Existing Share : Stock Dividend)	-	-	8 : 5
○ Stock Dividend Payout Ratio (Baht : Share)	-	-	0.3125
○ Cash Dividend Payout Ratio (Baht : Share)	-	-	0.0348
Dividend Payment to Net Profit Ratio (%)	60.00	-	62.12

The Chairman then invited the shareholders to express their opinions and raise questions relating to this agenda item. However, no shareholders expressed any opinions or raised any questions regarding this agenda item.

The Chairman therefore requested the meeting to consider and approve the allocation of profit as legal reserve and dividend payment for the year 2025.

Meeting Resolution: The meeting considered and resolved to approve the allocation of profit as legal reserve and dividend payment for the year 2025 with the following:

Agree	356,874,112	votes	% equivalent to 100.0000
Disagree	0	votes	% equivalent to 0.0000
Abstain	0	votes	% equivalent to 0.0000

Agenda 5 To consider and approve the remuneration of directors for the year 2026

The Chairman assigned Ms. Chompunuch Meevang, the Company Secretary, to inform the Meeting of the details regarding this agenda.

The Company Secretary informed the Meeting that according to Section 90 of the Public Limited Company Act B.E. 2535 (1992) (as amended) and Article 26 of the Company's Articles of Association, Directors are eligible for remuneration in forms of rewards, meeting allowance, gratuity, bonus or other benefit according to the resolution of the Shareholders' Meeting by not less than two-thirds (2/3) of the total number of votes of the shareholders attending the meeting and having the right to vote.

The Nomination and Remuneration Committee conducted a survey on remuneration for the Board of Directors and sub-committees for the year 2026, considering the suitability from the scope of duties and responsibilities, the responsibilities and performance of the Board of Directors and each sub-committee, business expansion, the Company's performance and comparative information with other companies in the same industry with similar size and nature of the business and considered appropriate to maintain the remuneration of the Board of Directors and sub-committees, including monthly remuneration and meeting allowance for the year 2026 (proposed year) at the same rate as year 2025.

The Board of Directors deemed it appropriate to propose to the Annual General Meeting of Shareholders to approve the remuneration of the Board of Directors and sub-committees for the year 2026 (proposed year) as proposed by the Nomination and Remuneration Committee who had taken into consideration various factors and criteria as follows:

Position	2026 (proposed year)	2025
Monthly remuneration (person : month) For non-executive directors <ul style="list-style-type: none"> ● Chairman ● Director 	30,000 Baht 20,000 Baht	30,000 Baht 20,000 Baht
Meeting Allowance For non-executive director (Baht : time) (pay only to meeting attendee) <u>Board of Directors</u> <ul style="list-style-type: none"> ● Chairman ● Director 	20,000 Baht 15,000 Baht	20,000 Baht 15,000 Baht

Position	2026 (proposed year)	2025
<u>Audit Committee</u>		
● Chairman	22,500 Baht	22,500 Baht
● Director	15,000 Baht	15,000 Baht
<u>Nomination and Remuneration Committee</u>		
● Chairman	15,000 Baht	15,000 Baht
● Director	10,000 Baht	10,000 Baht
<u>Corporate Governance and Sustainable Development Committee</u>		
● Chairman	15,000 Baht	15,000 Baht
● Director	10,000 Baht	10,000 Baht
<u>Risk Management Committee</u>		
● Chairman	15,000 Baht	15,000 Baht
● Director	10,000 Baht	10,000 Baht
Other Benefits	None	None

The Company has a policy of paying bonuses to independent directors and non-executive directors (whole board), the Company pays no more than 0.5 percent of the announced dividend amount. The monthly remuneration, meeting allowance and other benefits, the total amount must not exceed 4 Million Baht. By assigning the Board of Directors or the person assigned by the Board of Directors to consider and allocate bonuses to independent directors and non-executive directors.

In the year 2025, the total remuneration and bonuses for the Board of Directors and its subcommittees amounted to 2.51 Million Baht, which is within the above-mentioned criteria. Details are provided in the 2025 Annual Report (Form 56-1 One Report 2025), under Section 8: Key Corporate Governance Performance, Subsection 8.1.2: Directors' Remuneration.

The Chairman then invited the shareholders to express their opinions and raise questions relating to this agenda item. However, no shareholders expressed any opinions or raised any questions regarding this agenda item.

The Chairman therefore requested the meeting to consider and approve the remuneration of directors for the year 2026.

Meeting Resolution The meeting considered and resolved to approve the remuneration of directors for the year 2026 with a vote of not less than two-thirds of the total number of votes of the shareholders who attend the meeting and have the right to vote as follow:

Agree	356,874,112	votes	% equivalent to 100.0000
Disagree	0	votes	% equivalent to 0.0000
Abstain	0	votes	% equivalent to 0.0000

Agenda 6 To consider and approve the appointment of directors in replacement of those who must retire by rotation

The Chairman assigned Ms. Chompunuch Meevang, the Company Secretary, to inform the Meeting of the details regarding this agenda.

The Company Secretary informed the Meeting that the Section 71 of the Public Limited Company Act B.E. 2535 (1992) (including any amendment thereto) and Article 21 of the Company's Articles of Association, at every Annual General Meeting of Shareholders, one-third of the directors shall retire from office. If the number of directors cannot be divided exactly into three parts, the number closest to one-third shall retire. Directors retiring by rotation are eligible for re-election.

Currently, the Company has a total of 9 directors. Therefore, at the 2026 Annual General Meeting of Shareholders, 3 directors will be required to retire by rotation. The names of the directors due to retire are as follows:

1. Clinical Professor Emeritus Udom Kachintorn, MD. Independent Director, Chairman and Chairman of the Corporate Governance and Sustainable Development Committee
2. Dr. Trinnawat Thanitnithiphan Director, Nomination and Remuneration Committee, Risk Management Committee and Chairman of Executive Committee
3. Ms. Napaporn Dechakarat Director, Risk Management Committee and Executive Committee

The Company provides an opportunity for shareholders to propose agendas and nominate candidates to be elected as directors during October 1, 2025 – December 31, 2025, in which there were no shareholders proposing agendas and names of persons to be considered for election as a director.

The Nomination and Remuneration Committee (excluding the stakeholders) has carefully reviewed before presenting to the Board of Directors and to propose to the Annual General Meeting of Shareholders for election directors, considering the qualifications of directors as specified in the relevant laws, the Company's regulations, proportion and qualification of Independent Directors according to the definition of Independent Director of the Company, as well as knowledge, capabilities and experience that are useful to the Company's business. The Nomination and Remuneration Committee deemed it appropriate to propose the appointment of Clinical Professor Emeritus Udom Kachintorn, MD., Dr. Trinnawat Thanitnithiphan and Ms. Napaporn Dechakarat to return to serve as Directors for another term. The Nomination and Remuneration Committee considered that all candidates nominated have all qualifications as specified by relevant regulations

and suitable for the business, and the candidates nominated as independent directors are fully qualified in accordance with the law and regulations relating to independent directors and are able to provide opinions independently.

The Board of Directors (excluding stakeholders) considered the list of nominated persons, which has been carefully screened and considered by the Nomination and Remuneration Committee, and deemed it appropriate to propose to the Annual General Meeting of Shareholders to appoint 3 directors, namely Clinical Professor Emeritus Udom Kachintorn, MD., Dr. Trinawat Thanitnithiphan, and Ms. Napaporn Dechakarat to return to serve as Directors for another term. The Board of Directors considered that the candidates nominated as an Independent Directors have all qualifications as specified by relevant regulations and can provide independent opinions. Profiles and working experiences of the candidates nominated for election as the directors in place of those who retire by rotation in Attachment No. 3.

Thereafter, the Company Secretary invited the meeting to express opinions and raise questions regarding this agenda item. However, no shareholders expressed any opinions or raised any questions on this matter. The Company Secretary informed of the voting procedures for the election of directors, as detailed below.

Clause 19 of the Company's Articles of Association stipulates the director voting procedures as follows:

- (1) A shareholder shall have one vote for each share he holds or represents.
- (2) The shareholders shall vote for each individual candidate nominated for directors, but not exceeding the number of directors required for that election. The vote shall not be distributed.
- (3) The candidates shall be ranked in order descending from the highest number of votes received to the lowest, and shall be appointed as directors in that order until all of the director positions are filled. Where the votes cast for candidates in descending order are tied, which would otherwise cause the number of directors to be exceeded, the remaining appointment shall be made by the Chairman of the Meeting who shall have a casting vote.

For Agenda 6, the Meeting was requested to consider the candidates on an individual basis in the order as appeared in Agenda 6 of the Notice of the meeting, which showed the list of all nominated candidates.

The Company Secretary then proposed that the shareholders vote on the candidates on an individual basis, whereby this year there were four candidates nominated for election as directors to replace the directors due to retire by rotation, equivalent to the number of directors

Meeting Resolution: The meeting considered and resolved to approve the appointment of directors replacing those due to retire by rotation with the following votes:

(1) Clinical Professor Emeritus Udom Kachintorn, MD. Independent Director

Agree 356,874,112 votes % equivalent to 100.0000

Disagree 0 votes % equivalent to 0.0000

Abstain 0 votes % equivalent to 0.0000

(2) Dr. Trinawat Thanitnithiphan Director

Agree 356,874,112 votes % equivalent to 100.0000

Disagree 0 votes % equivalent to 0.0000

Abstain 0 votes % equivalent to 0.0000

(3) Ms. Napaporn Dechakarat Director

Agree 338,433,512 votes % equivalent to 94.8327

Disagree 18,440,600 votes % equivalent to 5.1673

Abstain 0 votes % equivalent to 0.0000

Agenda 7 To consider and approve the appointment of auditor and fix his/her remuneration for the year 2026

The Chairman assigned Ms. Chompunuch Meevang, the Company Secretary, to inform the Meeting of the details regarding this agenda.

The Company Secretary informed the Meeting that according to Section 120 of the Public Company Limited Act B.E. 2535 (1992) (as amended), which stipulates that the Annual General Meeting of Shareholders shall appoint auditors and determine audit fees every year. In appointing the auditor, the same auditor may be reappointed.

The Audit Committee has considered and approved the selection of auditors from EY Office Limited to be the auditors of the Company and its subsidiaries for the year 2026, which has been the same auditor for the sixth consecutive year. EY Office Limited has satisfactorily performed its duties to the Company in accordance with the auditing standards and provided useful opinions useful opinions to the Company and independent and agreed that the audit fee proposed by EY Office Limited was appropriate, when compared to the scope of service and workload.

With careful consideration Audit Committee, the Board of Directors deemed it appropriate to propose to the Annual General Meeting of Shareholders to appoint auditors from EY Office Limited, which is the same auditor as the Company's subsidiaries, whereby one of the following auditors will be appointed as the auditor of the Company for the year 2026.

1. Ms. Siriwan Nitdamrong Certified Public Accountant No. 5906 and / or
2. Ms. Kamonthip Lertwitworathep Certified Public Accountant No. 4377 and / or
3. Mrs. Sarinda Hirunprasurtwutti Certified Public Accountant No. 4799 and / or
4. Mr. Somsak Chiratdhitiampiyong Certified Public Accountant No. 8874

Ms. Siriwan Nitdamrong, Certified Public Accountant No. 5906, who has signed the company's financial statements since the 1st quarter of 2021 until the 2025 annual financial statements. All above four auditors are qualified and has no relationship or any conflict of interest with the Company, its subsidiaries and associates, management, major shareholders or any person related to such person. Therefore, there is independence in auditing and express an opinion on the Company's financial statements, its subsidiaries and associates including the certified auditors as above, no auditors have performed the audit duties of the Company for more than the period specified in the relevant announcement. (Profiles of the Auditors proposed for the year 2026, Attachment No. 4)

The Board of Directors also deemed it appropriate to propose to the Annual General Meeting of Shareholders to approve the audit fees of the Company for the year 2026 as follows:

(Unit : Baht)

List of services	2026 (proposed year)	2025	Increase/(Decrease)
Audit fee of the Company	2,380,000	2,180,000	200,000
Other service*	None	450,000	-

Remark: *Other service fees shall be charged based on actual expenses incurred.

The Chairman then invited the shareholders to express their opinions and raise questions relating to this agenda item. However, no shareholders expressed any opinions or raised any questions regarding this agenda item.

The Chairman therefore requested the meeting to consider and approve the appointment of auditor and fix his/her remuneration for the year 2026.

Meeting Resolution: The meeting considered and resolved to approve the appointment of auditor and fix his/her remuneration for the year 2026 with the following votes:

Agree	356,874,112	votes	% equivalent to	100.0000
Disagree	0	votes	% equivalent to	0.0000
Abstain	0	votes	% equivalent to	0.0000

Agenda 8 To consider and approve the issuance and offering of warrants to purchase of newly issued ordinary shares for allocation to Executive and/or Employees of the Company of Its Subsidiaries (IP ESOP-W1)

The Chairman assigned Ms. Chompunuch Meevang, the Company Secretary, to inform the Meeting of the details regarding this agenda.

The Company Secretary informed the Meeting that the Company intends to issue and offer warrants to purchase newly issued ordinary shares of the Company for allocation to executives and/or

employees of the Company or its subsidiaries (the “Warrants” or “IP ESOP-W1”) in an amount not exceeding 4,500,000 units, representing 0.74 percent of the total issued and outstanding shares. The Warrants will be allocated free of charge, with an exercise ratio of 1 warrant to 1 newly issued ordinary share, and a term of not exceeding 3 years from the issuance date. The objectives are to incentivize high-performing executives and employees and encourage their long-term commitment to achieving the Company’s business goals, as well as to retain knowledgeable and capable personnel with key skills critical to the Company’s core business. In addition, the issuance may help support the Company’s working capital if the Warrants are exercised, as detailed in Attachment No. 5.

In this regard, the Board of Directors and/or the Company’s authorized directors and/or any person(s) authorized by the Board of Directors or the Company’s authorized directors shall be authorized to consider and determine any other necessary details in connection with the issuance and allocation of IP ESOP-W1, including but not limited to:

- (1) Determining, the list of executives and/or employees of the Company or its subsidiaries who are entitled to receive the allocation of warrants and the number of warrants to be allocated to each individual;
- (2) Determining, amending, or adding any details and conditions necessary and related to the issuance of IP ESOP-W1 to the extent permitted by law or in non-material matters, such as the date, time, and method of issuance and allocation of IP ESOP-W1, and the method of exercise of the warrants;
- (3) Negotiating, entering into agreements, and executing relevant documents and contracts, and undertaking any actions in connection with the allocation of IP ESOP-W1; and
- (4) Signing applications for approval, and submitting relevant documents and evidence in connection with the allocation of IP ESOP-W1, including contacting and submitting applications and required documents to relevant government authorities, listing the newly issued ordinary shares on the Stock Exchange of Thailand, and taking any other necessary actions in relation to the allocation of IP ESOP-W1.

In addition, no executive or employee shall be allocated warrants in excess of 5 percent of the total number of warrants to be issued. The Company shall complete the allocation of the warrants within one (1) year from the date of approval by the shareholders’ meeting.

The Chairman then invited the shareholders to express their opinions and raise questions relating to this agenda item. However, no shareholders expressed any opinions or raised any questions regarding this agenda item.

The Chairman therefore requested the meeting to consider and approve the issuance and offering of warrants to purchase of newly issued ordinary shares for allocation to Executive and/or Employees of the Company of Its Subsidiaries (IP ESOP-W1).

Meeting Resolution: The meeting considered and resolved to approve the issuance and offering of warrants to purchase of newly issued ordinary shares for allocation to Executive and/or Employees of the Company of Its Subsidiaries (IP ESOP-W1) by a vote of not less than three-fourths (3/4) of the total votes of shareholders attending the meeting and eligible to vote, and with no shareholder or group of shareholders holding in aggregate more than ten percent (10 percent) of the total votes of shareholders attending the meeting casting opposing votes against the issuance and offering of the IP ESOP-W1 warrants, as follows:

Agree	356,874,112	votes	% equivalent to	100.0000
Disagree	0	votes	% equivalent to	0.0000
Abstain	0	votes	% equivalent to	0.0000

Agenda 9: To consider and approve the reduction of registered capital and the amendment to the Company's Memorandum of Association to reflect the capital reduction

The Chairman assigned Ms. Chompunuch Meevang, the Company Secretary, to inform the Meeting of the details regarding this agenda.

The Company Secretary informed the Meeting that to Section 136 of the Public Limited Companies Act B.E. 2535 (1992), as amended, a company may increase its capital only after all shares have been issued and fully paid, except for shares reserved for the exercise of warrants to purchase shares.

Currently, the Company has a registered capital of Baht 378,387,365, divided into 756,774,730 ordinary shares with a par value of Baht 0.50 per share, and a paid-up capital of Baht 302,672,237.50, divided into 605,344,475 ordinary shares with a par value of Baht 0.50 per share.

In this regard, the Company has 151,430,255 unissued ordinary shares, comprising:

1. Reserve for exercise the rights of the warrants to purchase ordinary shares of the Company No. 2 (IP-W2) of 93,129,515 shares;
2. Additionally, reserved for the adjustment of the rights of the warrants to purchase ordinary shares of the Company No. 2 (IP-W2) of 58,299,187 shares; and
3. Remaining from the reservation for stock dividend payment 1,553 shares

The Company shall reduce its registered capital of Baht 75,715,127.50 from the registered capital of Baht 378,387,365 to Baht 302,672,237.50 by canceling 151,430,255 shares unpaid-up ordinary shares with a par value of Baht 0.50 per share, and approve the amendment of Article 4 of the Company's Memorandum of Association to comply with the decrease of the Company's registered capital as follows;

"Article 4. Registered capital 302,672,237.50 Baht (Three hundred two million six hundred seventy-two thousand two hundred thirty-seven Baht and fifty Satang)

Divided into	605,344,475	shares	(Six hundred five million three hundred forty-four thousand four hundred seventy-five shares)
Par value	0.50	Baht	(Fifty Satang)
Divided into			
Ordinary shares	605,344,475	shares	(Six hundred five million three hundred forty-four thousand four hundred seventy-five shares)
Preferred shares	- None –	-"	

In addition, the Board of Directors deemed it appropriate to propose to the Annual General Meeting of Shareholders the authorization to the authorized directors of the Company in accordance with the Company's affidavit or any person authorized by such authorized directors to have the authority to undertake any necessary actions for the registration of the amendment of the Memorandum of Association as approved until completion.

The Chairman then invited the shareholders to express their opinions and raise questions relating to this agenda item. However, no shareholders expressed any opinions or raised any questions regarding this agenda item.

The Chairman therefore requested the meeting to consider and approve the reduction of registered capital and the amendment to Article 4 of the Company's Memorandum of Association to reflect the capital reduction.

Meeting Resolution The meeting considered and agreement the approve the reduction of registered capital and the amendment to Article 4 of the Company's Memorandum of Association to reflect the capital reduction with not less than three-fourths of the total number of votes of shareholders attending the meeting who are entitled to vote as follow:

Agree	356,874,112	votes	% equivalent to	100.0000
Disagree	0	votes	% equivalent to	0.0000
Abstain	0	votes	% equivalent to	0.0000

Agenda 10: To consider and approve the increase of registered capital and the amendment to the Company's Memorandum of Association to reflect the capital increase

The Chairman assigned Ms. Chompunuch Meevang, the Company Secretary, to inform the Meeting of the details regarding this agenda.

The Company Secretary informed the Meeting that the Company would like to increase its registered capital by Baht 2,250,000, from the existing registered capital of Baht 302,672,237.50 to Baht 304,922,237.50, by issuing 4,500,000 newly issued ordinary shares with a par value of Baht 0.50 per share, to

accommodate the exercise of warrants to purchase newly issued ordinary shares of the Company to be allocated to executives and/or employees of the Company or its subsidiaries (IP ESOP-W1), and to amend Clause 4 of the Company's Memorandum of Association to reflect such increase in registered capital as follows:

“Article 4. Registered capital	304,922,237.50	Baht	(Three hundred four million nine hundred twenty-two thousand two hundred thirty-seven Baht and fifty Satang)
Divided into	609,844,475	shares	(Six hundred nine million eight hundred forty-four thousand four hundred seventy-five shares)
Par value	0.50	Baht	(Fifty Satang)
Divided into			
Ordinary shares	609,844,475	shares	(Six hundred nine million eight hundred forty-four thousand four hundred seventy-five shares)
Preferred shares	- None –	-”	

In addition, the Board of Directors deemed it appropriate to propose to the Annual General Meeting of Shareholders the authorization to the authorized directors of the Company in accordance with the Company's affidavit or any person authorized by such authorized directors to have the authority to undertake any necessary actions for the registration of the amendment of the Memorandum of Association as approved until completion.

The Chairman then invited the shareholders to express their opinions and raise questions relating to this agenda item. However, no shareholders expressed any opinions or raised any questions regarding this agenda item.

The Chairman therefore requested the meeting to consider and approve the increase of registered capital and the amendment to Article 4 of the Company's Memorandum of Association to reflect the capital increase.

Meeting Resolution: The meeting considered and agreed to approve the increase of registered capital and the amendment to Article 4 of the Company's Memorandum of Association to reflect the capital increase with not less than three-fourths of the total number of votes of shareholders attending the meeting who are entitled to vote as follows:

Agree	356,874,112	votes	% equivalent to	100.0000
Disagree	0	votes	% equivalent to	0.0000
Abstain	0	votes	% equivalent to	0.0000

Agenda 11: To consider and approve the allocation of newly issued ordinary shares to accommodate the exercise of the IP ESOP-W1

The Chairman assigned Ms. Chompunuch Meevang, the Company Secretary, to inform the Meeting of the details regarding this agenda.

The Company Secretary informed the meeting that, following the registered capital increase plan under Agenda Item 10 above, the Company will allocate up to 4,500,000 newly issued ordinary shares to accommodate the exercise of rights under the IP ESOP-W1 warrants. These warrants will be allocated to the Company's executives and/or employees of the Company or its subsidiaries at a ratio of 1 existing ordinary share to 1 unit of warrant. The exercise price of the warrants is Baht 4.21 per share, as detailed in Attachment No. 5.

In this regard, the Board of Directors and/or the Chief Executive Officer and/or any person designated by the Board of Directors and/or the Chief Executive Officer shall be authorized to determine, amend, and change any terms and conditions and other details relating to the issuance and allocation of such newly issued ordinary shares, including but not limited to:

- (1) Changes to the conditions and other details related to the adjustment or change of the exercise ratio and exercise price, in accordance with the terms and conditions.
- (2) Entering into negotiations, make agreements, and sign relevant documents and contracts, as well as take any necessary and appropriate actions related to the allocation of the newly issued ordinary shares.
- (3) Sign the application for permission, waiver, and evidence necessary and related to the issuance and offering of such newly issued ordinary shares, including but not limited to providing information and submitting documents and evidence to the Securities and Exchange Commission, the Stock Exchange of Thailand, Thailand Securities Depository Co., Ltd., Ministry of Commerce, or other related agencies. They are also authorized to take any other actions necessary and relevant to the issuance and offering of such newly issued ordinary shares, including listing them as securities on the Stock Exchange of Thailand.
- (4) Take necessary action to reassemble and distribute the newly issued ordinary shares.

The Chairman then invited the shareholders to express their opinions and raise questions relating to this agenda item. However, no shareholders expressed any opinions or raised any questions regarding this agenda item.

The Chairman therefore requested the meeting to consider and approve the allocation of newly issued ordinary shares to accommodate the exercise of the IP ESOP-W1.

Meeting Resolution: The meeting considered and resolved to approve the allocation of newly issued ordinary shares to accommodate the exercise of the IP ESOP-W1 with the following votes:

Agree	356,874,112	votes	% equivalent to	100.000
Disagree	0	votes	% equivalent to	0.0000
Abstain	0	votes	% equivalent to	0.0000

Agenda 12 To consider any other matters (if any)

-None-

The Chairman gave the shareholders an opportunity to ask questions and express their additional opinions.

1. Mr. Jaturon Phonyos, a shareholder, inquired about the Company's plans for 2026.

Dr. Trinnawat Thanitnithiphan, Chief Executive Officer responded that, due to the war situation and the increase in oil prices, the Company anticipates a growth rate of 10 percent. The Company has also implemented measures to control and reduce unnecessary expenses.

2. Mr. Jaturon Phonyos, a shareholder, inquired about the branch expansion target for the pharmacy business in 2026.

Dr. Trinnawat Thanitnithiphan, Chief Executive Officer responded that, in 2026, the Company plans to close approximately 3 existing branches and open additional new branches, resulting in a total of approximately 50 branches.

3. Mr. Jaturon Phonyos, a shareholder, inquired whether there were any issues regarding pharmaceutical raw materials and how the Company planned to address them.

Dr. Trinnawat Thanitnithiphan, Chief Executive Officer responded that, upon learning about the war situation, the Company immediately began stocking raw materials, and therefore no shortages had occurred. However, transportation costs had increased significantly. Regarding product price adjustments, the Company would monitor signals from the manufacturers as to whether price increases would be implemented.

4. Mr. Jaturon Phonyos, a shareholder, inquired about the number of inpatient department (IPD) beds currently available at the hospital and whether there were plans to increase the number of beds.

Dr. Trinnawat Thanitnithiphan, Chief Executive Officer responded that the hospital currently has a total of 59 beds in operation. Following the Company's acquisition of a 50 percent shareholding, the hospital was renamed "Nakornpat Inter Hospital." The Company also plans to renovate and develop several areas of the hospital, including the outpatient department (OPD), inpatient department (IPD), MRI Center, CT Scan Center, and a new Cath Lab Center, as well as expand outpatient services. In addition, the Company plans to increase bed capacity in the future and is currently preparing for a listing on the Market for Alternative

Investment (mai) in order to raise funds for the construction of a new hospital building, which is expected to accommodate approximately 100 beds. The hospital currently occupies approximately 7 rai of land, of which only around 3 rai are presently utilized, leaving substantial potential for future building expansion and project development. The Company therefore considers fundraising through the capital market to be more appropriate than borrowing from financial institutions.

5. Mr. Jaturon Phonyos, a shareholder, inquired whether, after nearly four months of operations, the Company's operating results in terms of revenue and profit remained in line with the targets set for 2026.

Dr. Trinnawat Thanitnithiphan, Chief Executive Officer responded that the Company's operating results currently remained in line with the established targets. However, the Company continues to closely monitor and review the situation due to various external factors, such as the war situation, rising oil prices, and potentially weakened consumer purchasing power, all of which may affect business operations in several aspects. On the other hand, such circumstances may positively impact demand for products, particularly medicines and medical supplies for chronic diseases, as customers may stockpile products to mitigate the risk of shortages, similar to what occurred during the COVID-19 pandemic, when hospitals significantly increased their purchase orders. Accordingly, the Company places importance on inventory management to ensure sufficient stock levels to meet customer demand and maintain continuous product delivery under all circumstances.

6. Mr. Jaturon Phonyos, a shareholder, inquired whether the Company planned to enter into any additional mergers and acquisitions (M&A) transactions.

Dr. Trinnawat Thanitnithiphan, Chief Executive Officer responded that there were currently no such plans.

7. Mr. Jaturon Phonyos, a shareholder, inquired whether the Company planned to reduce its marketing budget this year.

Dr. Trinnawat Thanitnithiphan, Chief Executive Officer responded that the Company expected such expenses to decrease, as it is currently focusing on cost management and reducing unnecessary expenditures.

8. Mr. Jaturon Phonyos, a shareholder, inquired what percentage of product cost was attributable to packaging costs.

Dr. Trinnawat Thanitnithiphan, Chief Executive Officer responded that the proportion depended on each product but was generally not high, as the Company's packaging materials were not particularly expensive.

9. Mr. Jaturon Phonyos, a shareholder, inquired whether the Company's revenue was primarily generated from OTC products or hospital sales.

Dr. Trinnawat Thanitnithiphan, Chief Executive Officer responded that the revenue proportions were relatively similar.

10. Mr. Jaturon Phonyos, a shareholder, inquired about the Company's concerns regarding its ability to achieve the 2026 targets.

Dr. Trinnawat Thanitnithiphan, Chief Executive Officer, responded that the Company had multiple business objectives, and management placed significant importance on closely and continuously monitoring various situations. The Company also regularly holds monthly meetings with managers and department heads to assess changes in the operating environment.

11. Mr. Jaturon Phonyos, a shareholder, inquired whether the Company had plans to develop injectable weight-loss medication.

Dr. Trinnawat Thanitnithiphan, Chief Executive Officer responded that the Company understood such products to be pen-type diabetes medications. Currently, domestic manufacturers are unable to produce such products because the relevant patents remain under protection and have not yet expired.

12. Several shareholders requested the Chief Executive Officer to report on the progress of obtaining EU Standard certification.

Dr. Trinnawat Thanitnithiphan, Chief Executive Officer responded that the Company had upgraded and improved the ophthalmic pharmaceutical manufacturing processes at the Inter Pharma factory located in Rojana Industrial Park 2, Phra Nakhon Si Ayutthaya Province. Most recently, an audit committee from Europe had completed an inspection of the factory during April 21–23, which marked a significant development, as the inspection schedule had previously been postponed from late last year. Following the audit, the committee would prepare an Audit Report, and the entire process was expected to take no less than 3–4 months. The report would also be reviewed by another group of consultants to assess the completeness and appropriateness of the audit results before proceeding to the approval stage, provided that no further corrective actions were required. The Company expected the entire process, from inspection to conclusion, to take approximately 120 days. The inspection had originally been scheduled for October–November of the previous year, but due to unrest during that period, the inspection was postponed to April of this year instead.

As there were no further matters proposed by the shareholders or additional questions raised, the Chairman thanked all shareholders for attending the meeting and declared the meeting closed at 15.25 hrs.

-Signature-

(Clinical Professor Emeritus Dr. Udom Kachintorn)

Chairman of the Board of Directors

-Signature-

(Ms. Chompunuch Meevang)

Company Secretary